产品名称 | CPI 0610 |
产品货号 | Axon 2594 CAS [1380087-89-7] MF C20H16ClN3O2MW 365.81 Purity: 99% Soluble in DMSO Description Selective and metabolically stable inhibitor of the BET family of bromodomains (BET-BRD; IC50 values 0.12 - 0.17 µM and 0.22 µM for inhibition of BD-1 of BRD2-4 and BRDT, respectively), demonstrating a correlation between BET-driven reduction in MYC gene expression and tumor growth inhibition in a xenograft study. CPI 0610 displays essentially no activity in TR-FRET- or AlphaLisabased assays against the bromodomains of CBP, BRD9, BRPF1, PCAF, BRG1, ATAD2, TRIM24, BRD8 (IC50 value > 15 µM), and no meaningful inhibition in a CEREP express panel of about 50 GPCRs, ion channels, and transporters. *Constellation Pharmaceuticals Inc compound; sold under agreement with Constellation Pharmaceuticals Inc. |
产品价格 | 现货询价,电话:010-67529703 |
产品规格 | |
产品品牌 | axonmedchem |
产品概述 | |
产品详情 |
CPI 0610Axon 2594 CAS [1380087-89-7] MF C20H16ClN3O2
DescriptionSelective and metabolically stable inhibitor of the BET family of bromodomains (BET-BRD; IC50 values 0.12 - 0.17 µM and 0.22 µM for inhibition of BD-1 of BRD2-4 and BRDT, respectively), demonstrating a correlation between BET-driven reduction in MYC gene expression and tumor growth inhibition in a xenograft study. CPI 0610 displays essentially no activity in TR-FRET- or AlphaLisabased assays against the bromodomains of CBP, BRD9, BRPF1, PCAF, BRG1, ATAD2, TRIM24, BRD8 (IC50 value > 15 µM), and no meaningful inhibition in a CEREP express panel of about 50 GPCRs, ion channels, and transporters. *Constellation Pharmaceuticals Inc compound; sold under agreement with Constellation Pharmaceuticals Inc. KEYWORDS: CPI 0610 | supplier | BET-BRD inhibitor | CPI0610 | CAS [1380087-89-7] | [1845726-14-8] | Histone | BET(BRD) | Inhibitor | Bromodomain | BRD2 | BRD3 | BRD4 | BRDT | DNA | histone | epigenetic | apoptosis
Selective and metabolically stable inhibitor of BET bromodomains
Chemical name2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[e]isoxazolo[5,4-c]azepin-4-yl)acetamide Source informationConstellation Pharmaceuticals Inc compound; sold under agreement with Constellation Pharmaceuticals Inc.Parent CAS No.[1380087-89-7] |
产品资料 |